DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Retinoic Acid Homeostasis in Major Depression

Information source: Charite University, Berlin, Germany
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depression

Phase: N/A

Status: Recruiting

Sponsored by: Charite University, Berlin, Germany

Official(s) and/or principal investigator(s):
Isabella Heuser, MD, PhD, Principal Investigator, Affiliation: Chair: Department of Psychiatry, Charité, CBF

Overall contact:
Julian Hellmann-Regen, MD, Email: Julian.Hellmann@charite.de

Summary

It is hypothesized, that local retinoic acid (RA) homeostasis is functionally involved in the pathophysiology of depression. In a cross-sectional analysis healthy controls and depressed patients, serum RA status will be assessed.

Clinical Details

Official title: Retinoic Acid Homeostasis in Major Depression

Study design: Observational Model: Case Control, Time Perspective: Cross-Sectional

Primary outcome: Serum retinoic acid (RA) levels [nM]

Secondary outcome:

Montgomery-Asberg Depression Rating Scale (MADRS)

Serum retinoic acid (RA) levels [nM]

Serum retinoic acid (RA) levels [nM]

phenotyping of peripheral white blood cells

Beck Depression Inventory (BDI)

Investigation of RA homeostasis-related gene transcription in patient-derived cells.

Detailed description: Retinoids comprise of a group of small-molecule derivatives of Vitamin A with retinoic acid (RA) representing the biologically most active endogenous form. RA has multiple functions central nervous system (CNS). It is hypothesized, that local RA homeostasis is functionally involved in the pathophysiology of depression. In a cross-sectional analysis healthy controls and depressed patients, serum RA status will be assessed.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

MDD-Group Inclusion Criteria:

- depressive episode in the context of unipolar major depression

- at least 18 points or more on the BDI and HAMD-17

Exclusion Criteria:

- additional or comorbid axis-I or axis-II disorder current history of any neurological

or other serious medical condition

- any psychopharmacological treatment or substance use within the last two weeks or 5

half-lives (whichever is longer) of the respective substance

- any oral or topical application of retinoid-containing preparations within the last 3

months

Locations and Contacts

Julian Hellmann-Regen, MD, Email: Julian.Hellmann@charite.de

Department of Psychiatry, Charité - Campus Benjamin Franklin, Berlin 12203, Germany; Recruiting
Additional Information

Starting date: March 2015
Last updated: May 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017